High-density lipoprotein cholesterol
Importance for reduction of cardiovascular disease risk

High-density lipoprotein, HDL, is one of the hottest topics in lipid research and cardiovascular disease prevention today. Epidemiological studies have established low HDL cholesterol as an important independent risk factor for cardiovascular disease. Recent research also shows that HDL plays a key role in the prevention, or even reversal, of atherosclerosis. Treatment guidelines recognise the importance of managing low HDL cholesterol to reduce the risk of premature cardiovascular disease, especially in diabetes and metabolic syndrome.

HDL Forum provides:

Register NOW to receive the new expanded edition of High Density Cholesterol: the new target at a special price!

Correspondence is welcome – see details in Submission Info

Members of the Editorial Board of HDL Forum are internationally known for innovative leadership in HDL research, atherosclerosis and cardiovascular disease prevention.

  • Professor Kerry-Anne Rye, Lead Editor of HDL Forum: Professor in the Faculty of Medicine, University of Sydney, and Associate Director and Head of the Lipid Research Group, Heart Research Institute, Sydney, Australia.
    View CV | Heart Research Institute
  • Professor Philip Barter: Professor of Medicine, University of Sydney and Director of the Heart Research Institute, Sydney, Australia.
    View CV | Heart Research Institute
  • Dr H Bryan Brewer: Director of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington DC, USA.
    View CV | MedStar Research Institute
  • Professor Alan Chait: Edwin L. Bierman Professor of Medicine, Head, Division of Metabolism, Endocrinology and Nutrition and Director of Clinical Nutrition Research Unit, University of Washington, Seattle, USA.
    View CV | University of Washington, CNRU
  • Professor M John Chapman: Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute of Health and Medical Research (INSERM), Pitié-Salpétrière Hospital, Paris, France.
    View CV | Institute of Health and Medical Research
  • Professor John JP Kastelein: Professor of Medicine and Chairman of the Department of Vascular Medicine, Academic Medical Center of the University of Amsterdam, Strategic Chair of Genetics of Cardiovascular Disease and Director of the Atherosclerosis Research Group.
    View CV | AMC
  • Dr Anthony Wierzbicki: Director of the Lipid Unit, Guys’ and St. Thomas’ NHS Foundation Trust, London UK.
    View CV | Guys’ and St. Thomas’ NHS Foundation Trust